The first part of this article, which appeared in the August issue, discussed the benefits of the electronic health record, how to decide whether it is justified for a particular practice, and how to select and purchase a system. This second part provides guidance for installation and implementation.
CHICAGO—Pazopanib, a new oral angiogenesis inhibitor, may be effective in treating metastatic renal cell carcinoma (RCC), according to data from an ongoing phase II trial.
CHICAGO—Elevated plasma levels of C-reactive protein (CRP) predict worse survival in patients with androgen-independent prostate cancer (AIPC) receiving docetaxel-based therapy, a study found.
Urothiliasis afflicts 7%-13% of the population and has a recurrence rate of up to 50% at five years. In the United States, the economic burden of treatment and lost productivity was estimated at $2.1 billion in 2001.
Patients with end-stage renal disease (ESRD) are facing substantive challenges with the onset of the new Medicare Part D prescription drug program, a new survey by the American Kidney Fund (AKF) reports.
ALL TOO MANY investors face a common experience: They buy a top fund, and then the manager leaves. The new manager cant match the old results.
Millions of investors have been racing to buy exchange-traded funds (ETFs). Like index mutual funds, ETFs track benchmarks, such as the Standard Poors 500-stock index. But ETFs trade constantly on stock exchanges, while mutual funds are priced once a day.
Mistakes take a significant psychological toll on physicians, and health-care facilities do not help them cope, a new study concludes.
Local standards of practice should be relegated to the horse-and-buggy era where they started. They can discourage advances in medical practice and place extra burdens on physicians, especially those who practice in more than one state.
Electronic health records (EHRs) are creating a malpractice paradox, a pair of legal analysts says.
